We are thrilled to announce that we finally have the approval for our Phase 1b study to test OMO-103 in metastatic PDAC patients in combination with standard of care in first line! This is another milestone for peptomyc and its fantastic team. Stay tuned.
Source: Laura Soucek/Twitter